Home » Articles Posted by Julie

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to […]

High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – April 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high response and remission rates in anti-TNFα naïve patients in its recently completed randomized, placebo controlled trial in moderate to severe Crohn’s […]

Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – March 22nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to SSI therapy. […]

Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease

Vancouver, British Columbia – March 3, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, reports positive genetic analyses of their recently completed Phase 2 clinical studies in Crohn’s Disease (CD) and Ulcerative Colitis (UC). These findings suggest that, for the first […]

Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn’s Disease Clinical Trial

Vancouver, British Columbia – March 21, 2016 – Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced initial results from the QBECO-01 study, a 68-patient randomized, placebo-controlled clinical study for the treatment of moderate-to-severe Crohn’s disease. Based on the Week 8 and preliminary Week 16 results, […]

Qu Biologics Completes Enrollment of Randomized Clinical Trial in Crohn’s Disease

Vancouver, British Columbia – November 24, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has completed enrollment of its QBECO-01 Crohn’s disease clinical trial, with top-line data expected in late 1Q 2016. Qu Biologics’ QBECO-01 is […]

Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis

Vancouver, British Columbia – July 28, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted organ, announced that it has initiated a Phase 2 clinical trial to study QBECO SSI for the treatment of ulcerative colitis. Qu Biologics’ clinical trial in […]